Alisha Parker, DO
Nephrology · Meridian, MSNPI 1699154625
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,137 of the $1,531 with a category attached, or 74.3%. 14 manufacturers reported payments, led by Noah Medical Corporation at 25.7% of the total. Reporting peaked in 2023 at $578 and has fallen 59.2% since, to $236 in 2025. That places this record below the midpoint for nephrology clinicians in MS, where the typical reported total is $1,460.
Across 40 payments — averaging $38.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$394
- Bayer$227
- AstraZeneca$183
- Amgen$144
- Madrigal Pharmaceuticals$135
- Otsuka America Pharmaceutical, Inc.$92
- plus $356 from 8 others
What the payments were for
- Travel & lodging$39426%
- Food & beverage$1,13774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 2 | $394 |
| Bayer | 7 | $227 |
| AstraZeneca | 5 | $183 |
| Amgen | 2 | $144 |
| Madrigal Pharmaceuticals | 1 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Akebia Therapeutics Inc | 5 | $89 |
| Aurinia Pharma U.S., Inc. | 5 | $89 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Boehringer Ingelheim | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,531 in reported general payments places this provider in the 50th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 100 | $120,096 |
| FarxigaDapagliflozin Propanediol | 108 | $116,769 |
| VelphoroSucroferric Oxyhydroxide | 11 | $27,961 |
| KerendiaFinerenone | 29 | $23,644 |
| Febuxostat | 13 | $2,335 |
| Calcitriol | 60 | $1,506 |
| Sevelamer Carbonate | 12 | $1,276 |
| Losartan Potassium | 52 | $458 |
| Nifedipine ErNifedipine | 17 | $418 |
| Lisinopril | 44 | $258 |
| Cefdinir | 22 | $201 |
| Furosemide | 23 | $201 |
| Allopurinol | 27 | $194 |
| Carvedilol | 24 | $193 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 14 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $44 | $120,096100 claims |
| AstraZenecaFarxiga | $183 | $116,769108 claims |
| Fresenius USA Marketing, Inc.Velphoro | $15 | $27,96111 claims |
| BayerKerendia | $227 | $23,64429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Meridian
- Otis GowdyMeridian$12K
- John AndyMeridian$2K
- Robert ClarkMeridian$2K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Richard MillerBrookhaven$10K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.